Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Risk for at least one adverse event per patient · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriatic arthritis
Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults with SAnD
It is very uncertain whether comparison 13: SSRIs changes dropouts due to adverse events (long term) Post‐treatment: 1‐4 months compared with placebo (very low certainty).
1 finding from 1 review
Number of patients who withdrew because of adverse events · Patients with osteoarthritis of the knee or hip
Oral or transdermal opioids leads to higher number of participants who withdrew because of adverse events (median compared with placebo (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · children with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Adverse events: psychological disorders · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review
Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term compared with PLACEBO (very low certainty).
1 finding from 1 review
Dropouts due to adverse events · children and adolescents with trichotillomania
Glutamate modulators showed no clear difference in tolerability of treatment ‐ dropouts due to adverse eventscDropout… compared with placebo (low certainty).
1 finding from 1 review